How sphingolipids affect T cells in the resolution of inflammation

Jennifer Christina Hartel; Nadine Merz; Sabine Grösch

doi:10.3389/fphar.2022.1002915

How sphingolipids affect T cells in the resolution of inflammation

Front Pharmacol. 2022 Sep 13:13:1002915. doi: 10.3389/fphar.2022.1002915. eCollection 2022.

Authors

Jennifer Christina Hartel^{1

2}, Nadine Merz¹, Sabine Grösch^{1

3}

Affiliations

¹ Institute of Clinical Pharmacology, Goethe-University Frankfurt. Frankfurt am Main, Frankfurt, Germany.
² Department of Life Sciences, Goethe-University Frankfurt, Frankfurt, Germany.
³ Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany.

Abstract

The concept of proper resolution of inflammation rather than counteracting it, gained a lot of attention in the past few years. Re-assembly of tissue and cell homeostasis as well as establishment of adaptive immunity after inflammatory processes are the key events of resolution. Neutrophiles and macrophages are well described as promotors of resolution, but the role of T cells is poorly reviewed. It is also broadly known that sphingolipids and their imbalance influence membrane fluidity and cell signalling pathways resulting in inflammation associated diseases like inflammatory bowel disease (IBD), atherosclerosis or diabetes. In this review we highlight the role of sphingolipids in T cells in the context of resolution of inflammation to create an insight into new possible therapeutical approaches.

Keywords: S1P; Th17; bioactive lipids; ceramides; gangliosides; lipid rafts; treg.

Publication types

Review